These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 28488114)

  • 41. Analysis of risk factors for recurrence after curative resection of well-differentiated pancreatic neuroendocrine tumors based on the new grading classification.
    Tsutsumi K; Ohtsuka T; Fujino M; Nakashima H; Aishima S; Ueda J; Takahata S; Nakamura M; Oda Y; Tanaka M
    J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):418-25. PubMed ID: 24142395
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pancreatic neuroendocrine tumors containing areas of iso- or hypoattenuation in dynamic contrast-enhanced computed tomography: Spectrum of imaging findings and pathological grading.
    Hyodo R; Suzuki K; Ogawa H; Komada T; Naganawa S
    Eur J Radiol; 2015 Nov; 84(11):2103-9. PubMed ID: 26321494
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Surgical management of advanced pancreatic neuroendocrine tumors: short-term and long-term results from an international multi-institutional study.
    Birnbaum DJ; Turrini O; Vigano L; Russolillo N; Autret A; Moutardier V; Capussotti L; Le Treut YP; Delpero JR; Hardwigsen J
    Ann Surg Oncol; 2015 Mar; 22(3):1000-7. PubMed ID: 25190116
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparison of WHO 2000 and WHO 2010 classifications of gastroenteropancreatic neuroendocrine tumors.
    Karakuş E; Helvacı A; Ekinci O; Dursun A
    Turk J Gastroenterol; 2014 Feb; 25(1):81-7. PubMed ID: 24918137
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Value of Tumor Growth Rate (TGR) as an Early Biomarker Predictor of Patients' Outcome in Neuroendocrine Tumors (NET)-The GREPONET Study.
    Lamarca A; Crona J; Ronot M; Opalinska M; Lopez Lopez C; Pezzutti D; Najran P; Carvhalo L; Franca Bezerra RO; Borg P; Vietti Violi N; Vidal Trueba H; de Mestier L; Schaefer N; Sundin A; Costa F; Pavel M; Dromain C;
    Oncologist; 2019 Nov; 24(11):e1082-e1090. PubMed ID: 30910869
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A simple and practical index predicting the prognoses of the patients with well-differentiated pancreatic neuroendocrine neoplasms.
    Liu B; Kudo A; Kinowaki Y; Ogura T; Ogawa K; Ono H; Mitsunori Y; Ban D; Tanaka S; Akashi T; Tanabe M
    J Gastroenterol; 2019 Sep; 54(9):819-828. PubMed ID: 30863885
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Neutrophil-to-lymphocyte ratio predicts metachronous liver metastasis of pancreatic neuroendocrine tumors.
    Arima K; Okabe H; Hashimoto D; Chikamoto A; Nitta H; Higashi T; Kaida T; Yamamura K; Kitano Y; Komohara Y; Yamashita YI; Beppu T; Takeya M; Baba H
    Int J Clin Oncol; 2017 Aug; 22(4):734-739. PubMed ID: 28285371
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of the prognostic values of the 2010 WHO classification, AJCC 7th edition, and ENETS classification of gastric neuroendocrine tumors.
    Kim BS; Park YS; Yook JH; Kim BS
    Medicine (Baltimore); 2016 Jul; 95(30):e3977. PubMed ID: 27472674
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical course of neuroendocrine tumors with different origins (the pancreas, gastrointestinal tract, and lung).
    Kim SJ; Kim JW; Oh DY; Han SW; Lee SH; Kim DW; Im SA; Kim TY; Heo DS; Bang YJ
    Am J Clin Oncol; 2012 Dec; 35(6):549-56. PubMed ID: 21659833
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine neoplasms in a Chinese population: a large, retrospective single-centre study.
    Zhang M; Zhao P; Shi X; Zhao A; Zhang L; Zhou L
    BMC Endocr Disord; 2017 Jul; 17(1):39. PubMed ID: 28705205
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Neuroendocrine tumors of the pancreas: a retrospective single-center analysis using the ENETS TNM-classification and immunohistochemical markers for risk stratification.
    Brunner SM; Weber F; Werner JM; Agha A; Farkas SA; Schlitt HJ; Hornung M
    BMC Surg; 2015 Apr; 15():49. PubMed ID: 25928025
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prognostic factors and survival after surgical resection of pancreatic neuroendocrine tumor with validation of established and modified staging systems.
    Benetatos N; Hodson J; Marudanayagam R; Sutcliffe RP; Isaac JR; Ayuk J; Shah T; Roberts KJ
    Hepatobiliary Pancreat Dis Int; 2018 Apr; 17(2):169-175. PubMed ID: 29576279
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evaluation of Ki-67 index in EUS-FNA specimens for the assessment of malignancy risk in pancreatic neuroendocrine tumors.
    Hasegawa T; Yamao K; Hijioka S; Bhatia V; Mizuno N; Hara K; Imaoka H; Niwa Y; Tajika M; Kondo S; Tanaka T; Shimizu Y; Kinoshita T; Kohsaki T; Nishimori I; Iwasaki S; Saibara T; Hosoda W; Yatabe Y
    Endoscopy; 2014 Jan; 46(1):32-8. PubMed ID: 24218309
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients.
    Scarpa A; Mantovani W; Capelli P; Beghelli S; Boninsegna L; Bettini R; Panzuto F; Pederzoli P; delle Fave G; Falconi M
    Mod Pathol; 2010 Jun; 23(6):824-33. PubMed ID: 20305616
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Microscopic venous invasion in patients with pancreatic neuroendocrine tumor as a potential predictor of postoperative recurrence.
    Nanno Y; Toyama H; Otani K; Asari S; Goto T; Terai S; Ajiki T; Zen Y; Fukumoto T; Ku Y
    Pancreatology; 2016; 16(5):882-7. PubMed ID: 27350059
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Necrosis and angioinvasion predict adverse outcome in pancreatic neuroendocrine tumors after curative surgical resection: results of a single-center series.
    Demir R; Pohl J; Agaimy A; Peros G; Perrakis A; Merkel S; Hohenberger W; Klein P
    World J Surg; 2011 Dec; 35(12):2764-72. PubMed ID: 21927963
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pancreatic neuroendocrine neoplasms: Magnetic resonance imaging features according to grade and stage.
    De Robertis R; Cingarlini S; Tinazzi Martini P; Ortolani S; Butturini G; Landoni L; Regi P; Girelli R; Capelli P; Gobbo S; Tortora G; Scarpa A; Pederzoli P; D'Onofrio M
    World J Gastroenterol; 2017 Jan; 23(2):275-285. PubMed ID: 28127201
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparison of World Health Organization 2000/2004 and World Health Organization 2010 classifications for gastrointestinal and pancreatic neuroendocrine tumors.
    Pasaoglu E; Dursun N; Ozyalvacli G; Hacihasanoglu E; Behzatoglu K; Calay O
    Ann Diagn Pathol; 2015 Apr; 19(2):81-7. PubMed ID: 25702616
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Role of contrast-enhanced ultrasound to define prognosis and predict response to biotherapy in pancreatic neuroendocrine tumors.
    Del Prete M; Di Sarno A; Modica R; Lassandro F; Giorgio A; Bianco A; Muto M; Gasperi M; Del Prete F; Colao A; Montesarchio V; Faggiano A;
    J Endocrinol Invest; 2017 Dec; 40(12):1373-1380. PubMed ID: 28667452
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prediction of Tumor Prognosis of Pancreatic Neuroendocrine Tumors Using Image, Surgical and Pathologic Findings.
    Chen F; Huang Y; Chen C; Zhang Y; Zhang Y; Wan R; Xu M
    Neuro Endocrinol Lett; 2023 Oct; 44(7):453-464. PubMed ID: 37874552
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.